1. Home
  2. PDT vs VALN Comparison

PDT vs VALN Comparison

Compare PDT & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Hancock Premium Dividend Fund

PDT

John Hancock Premium Dividend Fund

N/A

Current Price

$11.55

Market Cap

581.9M

Sector

Finance

ML Signal

N/A

Logo Valneva SE

VALN

Valneva SE

N/A

Current Price

$5.16

Market Cap

582.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PDT
VALN
Founded
N/A
2012
Country
United States
France
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
581.9M
582.2M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
PDT
VALN
Price
$11.55
$5.16
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $12.28
AVG Volume (30 Days)
★ 136.0K
9.9K
Earning Date
01-01-0001
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$87.84
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.49
$4.75
52 Week High
$13.65
$12.18

Technical Indicators

Market Signals
Indicator
PDT
VALN
Relative Strength Index (RSI) 32.10 37.14
Support Level $11.49 $4.75
Resistance Level $13.02 $5.52
Average True Range (ATR) 0.17 0.21
MACD -0.05 -0.03
Stochastic Oscillator 1.34 0.00

Price Performance

Historical Comparison
PDT
VALN

About PDT John Hancock Premium Dividend Fund

John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest capital growth. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Share on Social Networks: